Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Glucagon575 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A25238 | 22059955 | Health Technol Assess | Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review. | 2011 | Details |
| A25266 | 22024495 | Nutr Res | Adverse metabolic effects of a hypercaloric, high-fat diet in rodents precede observable changes in body weight. | 2011 | Details |
| A25267 | 22024083 | Hepatogastroenterology | Sitagliptin as a novel treatment agent for non-alcoholic Fatty liver disease patients with type 2 diabetes mellitus. | 2012 | Details |
| A25290 | 21990953 | World J Gastroenterol | Potential risk factors for nonalcoholic steatohepatitis related to pancreatic secretions following pancreaticoduodenectomy. | 2011 | Details |
| A25321 | 21957486 | PLoS One | GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy. | 2011 | Details |
| A25499 | 21765869 | Therap Adv Gastroenterol | The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis. | 2011 | Details |
| A25528 | 21745271 | Liver Int | Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. | 2011 | Details |
| A25650 | 21595271 | Nihon Rinsho | [Attenuation of fatty accumulation in hepatocyte by incretin--expectation of novel medicine for treatment of NASH]. | 2011 | Details |
| A26012 | 21205607 | Orv Hetil | [Role of the brain in the regulation of metabolism and energy expenditure: the central role of insulin, and insulin resistance of the brain]. | 2011 | Details |
| A26020 | 22629789 | Eksp Klin Gastroenterol | [UDCA in the treatment of nonalcoholic fatty liver disease]. | 2011 | Details |
| A26443 | 20460915 | Dig Dis | Bile acids as regulators of hepatic lipid and glucose metabolism. | 2010 | Details |
| A26464 | 20444564 | Gastroenterol Clin Biol | Targeting the TGR5-GLP-1 pathway to combat type 2 diabetes and non-alcoholic fatty liver disease. | 2010 | Details |
| A26708 | 19923096 | Orv Hetil | [Role of the endocrine system in the pathogenesis of non-alcoholic fatty liver disease]. | 2009 | Details |
| A26709 | 19921118 | Adv Ther | Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status. | 2009 | Details |
| A26711 | 19915460 | Curr Opin Lipidol | Gut microbiota as a regulator of energy homeostasis and ectopic fat deposition: mechanisms and implications for metabolic disorders. | 2010 | Details |
| A27000 | 19370776 | World J Gastroenterol | Olive oil consumption and non-alcoholic fatty liver disease. | 2009 | Details |
| A27218 | 18956296 | Semin Liver Dis | Current and emerging therapies in nonalcoholic fatty liver disease. | 2008 | Details |
| A27482 | 19885351 | J Diabetes Sci Technol | Effects of exenatide on diabetes, obesity, cardiovascular risk factors, and hepatic biomarkers in patients with type 2 diabetes. | 2008 | Details |
| A27904 | 17053032 | J Physiol | High-fat diet-induced hepatic steatosis reduces glucagon receptor content in rat hepatocytes: potential interaction with acute exercise. | 2006 | Details |
| A28120 | 16374859 | Hepatology | Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. | 2006 | Details |
| A28451 | 14631324 | Diabetes Metab | Contribution of hepatic de novo lipogenesis and reesterification of plasma non esterified fatty acids to plasma triglyceride synthesis during non-alcoholic fatty liver disease. | 2003 | Details |
| A29068 | 34626851 | Mol Metab | GLP-1 physiology informs the pharmacotherapy of obesity. | 2021 | Details |
| A29246 | 34363605 | J Physiol Biochem | HGF can reduce accumulation of inflammation and regulate glucose homeostasis in T2D mice. | 2021 | Details |
| A29479 | 34016612 | Diabetes Care | Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study. | 2021 | Details |
| A29839 | 33422984 | Eur J Med Chem | Design of novel Xenopus GLP-1-based dual glucagon-like peptide 1 (GLP-1)/glucagon receptor agonists. | 2020 | Details |
| A29923 | 33268008 | Bioorg Chem | Discovery of a novel GLP-1/GIP dual receptor agonist CY-5 as long-acting hypoglycemic, anti-obesity agent. | 2020 | Details |
| A30300 | 32682196 | Eur J Med Chem | A novel long-acting oxyntomodulin analogue eliminates diabetes and obesity in mice. | 2020 | Details |
| A30599 | 32140659 | Hepatol Commun | Pirfenidone Is an Agonistic Ligand for PPARα and Improves NASH by Activation of SIRT1/LKB1/pAMPK. | 2020 | Details |
| A32389 | 28576430 | Drug Discov Today | Gastric bypass surgery mimetic approaches. | 2017 | Details |
| A33056 | 26774017 | Diabetes Metab | Pleiotropic effects of insulin and GLP-1 receptor agonists: Potential benefits of the association. | 2015 | Details |
| A34157 | 26202296 | Hepatol Int | Insulin resistance: mechanism and implications for carcinogenesis and hepatocellular carcinoma in NASH. | 2013 | Details |
| A34187 | 24189085 | BMJ Open | Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial. | 2013 | Details |
| A34505 | 23293533 | J Inflamm Res | Alleviation of insulin resistance and liver damage by oral administration of Imm124-E is mediated by increased Tregs and associated with increased serum GLP-1 and adiponectin: results of a phase I/II clinical trial in NASH. | 2012 | Details |
| A36985 | 16772459 | J Nutr | Propionate challenge tests have limited value for investigating bovine metabolism. | 2006 | Details |
| A42371 | 34741327 | Aliment Pharmacol Ther | Editorial: evolution of GLP-1 receptor agonists as pharmacotherapy for NASH beyond diabetes mellitus and obesity - authors' reply. | 2021 | Details |
| A42372 | 34741326 | Aliment Pharmacol Ther | Editorial: evolution of GLP-1 receptor agonists as pharmacotherapy for NASH beyond diabetes mellitus and obesity. | 2021 | Details |
| A42498 | 34366254 | Dig Liver Dis | GLP-1 receptor agonists and reduction of liver fat content in NAFLD patients: Just a question of weight loss? | 2021 | Details |
| A42530 | 34233105 | N Engl J Med | Semaglutide or Placebo for Nonalcoholic Steatohepatitis. Reply. | 2021 | Details |
| A42531 | 34233104 | N Engl J Med | Semaglutide or Placebo for Nonalcoholic Steatohepatitis. | 2021 | Details |
| A42614 | 34015974 | Expert Rev Clin Pharmacol | Update on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome. | 2021 | Details |
| A42632 | 33960005 | Hepatology | The Glucagon-Like Peptide-1 Receptor Agonist, Semaglutide, for the Treatment of Nonalcoholic Steatohepatitis. | 2021 | Details |
| A42801 | 33442011 | Nat Med | Therapy for NASH. | 2021 | Details |
| A42864 | 33257834 | Nat Rev Gastroenterol Hepatol | Semaglutide is safe and efficacious for NASH resolution. | 2021 | Details |
| A42889 | 33189580 | Can J Diabetes | Practical Considerations and Rationale for Glucagon-Like Peptide-1 Receptor Agonist Plus Sodium-Dependent Glucose Cotransporter-2 Inhibitor Combination Therapy in Type 2 Diabetes. | 2020 | Details |
| A42934 | 33044023 | J Cell Physiol | Exenatide improves random-pattern skin flap survival via TFE3 mediated autophagy augment. | 2020 | Details |
| A43066 | 32646248 | Expert Opin Drug Discov | What is on the horizon for type 2 diabetes pharmacotherapy? - An overview of the antidiabetic drug development pipeline. | 2020 | Details |
| A43419 | 31764586 | J Hypertens | Cardiovascular, renal and liver protection with novel antidiabetic agents beyond blood glucose lowering in type 2 diabetes: consensus article from the European Society of Hypertension Working Group on Obesity, Diabetes and the High-risk Patient. | 2020 | Details |
| A43506 | 31566590 | Pol Arch Intern Med | Pentraxin 3 in patients with type 2 diabetes and nonalcoholic fatty liver disease: a promising treatment target for glucagon-like peptide-1 receptor agonists. | 2019 | Details |
| A43507 | 31566589 | Pol Arch Intern Med | Pentraxin 3 in patients with type 2 diabetes and nonalcoholic fatty liver disease: a promising treatment target for glucagon-like peptide-1 receptor agonists. Authors' reply. | 2019 | Details |
| A43639 | 31237448 | Am J Physiol Endocrinol Metab | Obeticholic acid ameliorates dyslipidemia but not glucose tolerance in mouse model of gestational diabetes. | 2019 | Details |
| A43827 | 30770439 | Proc Natl Acad Sci U S A | PGC1A regulates the IRS1:IRS2 ratio during fasting to influence hepatic metabolism downstream of insulin. | 2019 | Details |
| A43871 | 30641759 | Diabetes Metab Syndr | Relationship between glucagon like peptide-1 and non-alcoholic fatty liver disease in diabetic and non-diabetic patients. | 2018 | Details |
| A43957 | 30325692 | Metab Syndr Relat Disord | Determinants of Fasting Hyperglucagonemia in Patients with Type 2 Diabetes and Nondiabetic Control Subjects. | 2018 | Details |
| A43978 | 30253173 | Toxicol Appl Pharmacol | Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces hepatic steatosis and endoplasmic reticulum stress by inducing nuclear factor erythroid-derived 2-related factor 2 nuclear translocation. | 2018 | Details |
| A43989 | 30215326 | Cardiovasc Hematol Agents Med Chem | Cardiovascular and Hematological Medicine in 2018 - Advances and Insights. | 2019 | Details |
| A44116 | 29702499 | Curr Opin Cardiol | New antihyperglycaemic agents and cardiovascular disease: let's be optimistic. | 2018 | Details |
| A44225 | 29327584 | J Agric Food Chem | Gamma-aminobutyric Acid Enriched Rice Bran Diet Attenuates Insulin Resistance and Balances Energy Expenditure via Modification of Gut Microbiota and Short-Chain Fatty Acids. | 2018 | Details |
| A44501 | 28459036 | Indian J Endocrinol Metab | Consensus Statement on Dose Modifications of Antidiabetic Agents in Patients with Hepatic Impairment. | 2020 | Details |
| A44508 | 28434491 | Lancet Diabetes Endocrinol | Semaglutide, lipid-lowering drugs, and NAFLD - Author's reply. | 2017 | Details |
| A44509 | 28434490 | Lancet Diabetes Endocrinol | Semaglutide, lipid-lowering drugs, and NAFLD. | 2017 | Details |
| A44597 | 28061944 | Nutr Metab Cardiovasc Dis | Comments on "Insulin resistance, postprandial GLP-1 and adaptive immunity are the main predictors of NAFLD in a homogeneous population at high cardiovascular risk". | 2017 | Details |
| A44626 | 27914695 | Nutr Metab Cardiovasc Dis | Reply from the authors to "Comments on 'Insulin resistance, postprandial GLP-1 and adaptive immunity are the main predictors of NAFLD in a homogeneous population at high cardiovascular risk'". | 2016 | Details |
| A44711 | 27633289 | Curr Vasc Pharmacol | Editorial: Can Glucagon Like Peptide 1 (GLP1) Agonists or Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors Ameliorate Non-Alcoholic Steatohepatitis in People with or without Diabetes? | 2016 | Details |
| A44821 | 27181498 | J Diabetes Investig | Managing non-alcoholic fatty liver disease in diabetes: Challenges and opportunities. | 2016 | Details |
| A44946 | 26643784 | J Hepatol | Time for Glucagon like peptide-1 receptor agonists treatment for patients with NAFLD? | 2015 | Details |
| A45068 | 26194078 | Endocrinol Metab (Seoul) | Exendin-4 Inhibits the Expression of SEPP1 and Fetuin-A via Improvement of Palmitic Acid-Induced Endoplasmic Reticulum Stress by AMPK. | 2014 | Details |
| A45096 | 26087519 | Zhonghua Gan Zang Bing Za Zhi | [Effect of glucagon-like peptide 1 on nonalcoholic fatty liver disease]. | 2015 | Details |
| A45301 | 25287814 | J Nutr Biochem | High-protein diets prevent steatosis and induce hepatic accumulation of monomethyl branched-chain fatty acids. | 2014 | Details |
| A45312 | 25230688 | Mol Med Rep | Liraglutide reduces lipid accumulation in steatotic L‑02 cells by enhancing autophagy. | 2014 | Details |
| A45325 | 25177166 | Korean J Physiol Pharmacol | Exendin-4 Improves Nonalcoholic Fatty Liver Disease by Regulating Glucose Transporter 4 Expression in ob/ob Mice. | 2014 | Details |
| A45486 | 24361124 | Gastroenterology | Gluconeogenic signals regulate iron homeostasis via hepcidin in mice. | 2013 | Details |
| A45611 | 23680744 | Hosp Pract (1995) | Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus. | 2013 | Details |
| A45751 | 22960075 | Am J Pathol | The glucagon-like peptide-1 receptor agonist Exendin 4 has a protective role in ischemic injury of lean and steatotic liver by inhibiting cell death and stimulating lipolysis. | 2012 | Details |
| A45853 | 22383493 | Am J Physiol Gastrointest Liver Physiol | When GLP-1 hits the liver: a novel approach for insulin resistance and NASH. | 2012 | Details |
| A45918 | 22093450 | Liver Int | Glucagon like-peptide 1 receptor and the liver. | 2011 | Details |
| A46119 | 20962018 | J Clin Endocrinol Metab | The metabolic phenotype of Prader-Willi syndrome (PWS) in childhood: heightened insulin sensitivity relative to body mass index. | 2010 | Details |
| A46216 | 20225248 | Hepatology | Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. | 2010 | Details |
| A47018 | 29708448 | Expert Opin Pharmacother | Alcoholic steatohepatitis (ASH) and alcoholic hepatitis (AH): cascade of events, clinical aspects, and pharmacotherapy options. | 2018 | Details |
| A47428 | 8729827 | Ann Dermatol Venereol | [Necrolytic migrating erythema without glucagonoma]. | 1995 | Details |
| A47601 | 35235191 | Clin Pharmacokinet | Population Pharmacokinetics of Cotadutide in Subjects with Type 2 Diabetes. | 2022 | Details |
| A47643 | 34430533 | Hepatobiliary Surg Nutr | Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic steatohepatitis: new insights from subcutaneous semaglutide. | 2021 | Details |
| A47679 | 33778934 | Clin Pharmacokinet | Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide. | 2021 | Details |
| A47719 | 33030356 | Expert Rev Endocrinol Metab | Tirzepatide: a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetes. | 2020 | Details |
| A47735 | 32730231 | JCI Insight | Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. | 2020 | Details |
| A47824 | 31301451 | Clin Gastroenterol Hepatol | Effects of Fecal Microbiota Transplantation With Oral Capsules in Obese Patients. | 2019 | Details |
| A47858 | 30742277 | Drugs | The Impact of Comorbidities on the Pharmacological Management of Type 2 Diabetes Mellitus. | 2019 | Details |
| A47881 | 30141927 | J Med Chem | Design of Gut-Restricted Thiazolidine Agonists of G Protein-Coupled Bile Acid Receptor 1 (GPBAR1, TGR5). | 2018 | Details |
| A47896 | 29870275 | Diabetes Technol Ther | The Clinical Impact of GLP-1 Receptor Agonists in Type 2 Diabetes: Focus on the Long-Acting Analogs. | 2018 | Details |
| A47935 | 28847797 | Circulation | Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors. | 2017 | Details |
| A47936 | 30992756 | Clin Liver Dis (Hoboken) | Glucagon-like peptide-1 analogues in nonalcoholic steatohepatitis: From bench to bedside. | 2017 | Details |
| A47990 | 27110066 | Mediators Inflamm | Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control. | 2016 | Details |
| A48182 | 20529882 | J Lipid Res | Glucagon regulates intracellular distribution of adipose differentiation-related protein during triacylglycerol accumulation in the liver. | 2010 | Details |
| A48481 | 8234924 | Recent Dev Alcohol | Recent developments in alcoholism:the liver. | 1993 | Details |
| A48534 | 34605124 | Diabetes Obes Metab | Effects of glucagon-like peptide-1 receptor agonists on histopathological and secondary biomarkers of non-alcoholic steatohepatitis: A systematic review and meta-analysis. | 2021 | Details |
| A48549 | 34267725 | Front Endocrinol (Lausanne) | Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide. | 2021 | Details |
| A48558 | 34137731 | Endocr Connect | How glucagon-like peptide 1 receptor agonists work. | 2021 | Details |
| A48656 | 32195457 | JHEP Rep | miR-22 inhibition reduces hepatic steatosis via FGF21 and FGFR1 induction. | 2020 | Details |
| A48746 | 29926478 | Br J Clin Pharmacol | MEDI0382, a GLP-1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single-dose, healthy-subject, randomized, Phase 1 study. | 2018 | Details |
| A48819 | 27639537 | Lancet Diabetes Endocrinol | Clinical relevance of the bile acid receptor TGR5 in metabolism. | 2016 | Details |
| A49042 | 20383479 | Internist (Berl) | [Hormonal and metabolic functions of the small intestine]. | 2010 | Details |